Thyroid Eye Disease Treatment Landscape Gains a Third Major Drug Development Contender

Introduction

The thyroid eye disease (TED) treatment market is entering a more competitive phase as a third major drug-development contender emerges around the same biological target that has already transformed the field. Khartis Therapeutics has emerged from stealth with $95 million in total financing and an oral selective insulin-like growth factor 1 receptor (IGF-1R) inhibitor designed for TED.

The development is significant because TED has historically had limited targeted treatment options. Amgen's Tepezza (teprotumumab) established IGF-1R inhibition as a clinically validated approach, while Viridian Therapeutics' Lumvoa (veligrotug-vvze) received U.S. FDA approval in 2026, creating the first direct commercial competition in the market.

Khartis is therefore entering a market that is no longer defined simply by whether IGF-1R can work, but by how effectively the next generation of therapies can improve administration, patient convenience, durability and access.

IGF-1R Has Become a Validated Target in TED

The emergence of Khartis reflects the growing importance of IGF-1R biology in TED. The pathway has become one of the most important therapeutic targets in the disease after Tepezza demonstrated that targeting IGF-1R could produce meaningful improvements in disease manifestations such as proptosis and diplopia.

Tepezza remains an important benchmark for developers. Amgen has also been working to expand its treatment proposition beyond intravenous administration. In April 2026, the company reported positive Phase 3 results for a subcutaneous version of Tepezza, indicating that administration convenience is becoming an important competitive dimension.

This creates a more mature competitive environment: developers now have to demonstrate not only biological activity but also why their product could be preferable to established or emerging alternatives.

Viridian Creates the Second Commercial Benchmark

Viridian Therapeutics has significantly changed the competitive landscape with Lumvoa. The FDA approved Lumvoa in June 2026 for TED regardless of disease activity or duration. The drug is a full IGF-1R antagonist and is administered through five intravenous infusions over 12 weeks, with doses given every three weeks.

Viridian's development strategy also illustrates the value of improving treatment convenience. Its earlier-stage elegrobart program has explored subcutaneous administration, while Phase 3 results in chronic TED demonstrated positive proptosis responder rates for both four-week and eight-week dosing schedules.

The result is a market increasingly focused on differentiating the treatment experience rather than simply reproducing IGF-1R inhibition.

Khartis Brings an Oral Approach

Khartis introduces a different proposition: an oral, selective IGF-1R inhibitor.

The company's lead program is designed specifically for TED and is intended to advance toward clinical development following its $50 million Series B financing. The financing brought Khartis' total capital raised to approximately $95 million and is also supporting a broader pipeline of oral small-molecule medicines aimed at clinically validated immunology pathways.

The distinction between an oral small molecule and an infused biologic could become strategically important.

An oral therapy could potentially:

• eliminate infusion-center visits;

• simplify treatment administration;

• improve patient convenience;

• create opportunities for different treatment settings;

• potentially provide physicians with another option for patients who are not ideal candidates for infusion-based therapy.

However, these remain potential advantages rather than demonstrated clinical benefits. Khartis' program is still advancing toward the clinic, meaning its efficacy, safety, dosing schedule and long-term performance have yet to be established in patients.

Three-Way Competition Is Emerging

The TED market can increasingly be viewed through three different development strategies:

This comparison shows why Khartis' entry is strategically interesting. The company does not appear to be pursuing an entirely novel biological target. Instead, it is attempting to improve the delivery format and potentially the treatment profile around a target that has already been clinically validated.

That can reduce some biological uncertainty while shifting the competitive challenge toward medicinal chemistry, selectivity, pharmacokinetics, safety and clinical differentiation.

The Market Is Moving Beyond a Single-Product Model

The evolution of TED treatment also demonstrates how successful validation of a biological pathway can create an ecosystem of follow-on innovation.

Tepezza established the commercial value of IGF-1R inhibition. Viridian subsequently demonstrated that another company could compete around the same mechanism with a different antibody and treatment schedule. Khartis is now testing whether the mechanism can be translated into an oral small-molecule format.

This progression is relevant beyond TED. Once a disease pathway becomes clinically validated, investment can shift from target discovery toward optimization of:

• molecular selectivity;

• route of administration;

• dosing frequency;

• treatment duration;

• patient segmentation;

• safety and tolerability;

• manufacturing economics;

• healthcare-system convenience.

For biotechnology investors, this can make validated mechanisms attractive platforms for differentiated follow-on products.

Procurement and Commercial Implications

The growing number of TED developers could also create a broader pharmaceutical supply-chain opportunity.

An oral small-molecule program requires a different manufacturing and sourcing ecosystem from an antibody-based therapy. As Khartis advances, potential requirements could include specialized active pharmaceutical ingredient manufacturing, medicinal-chemistry intermediates, analytical testing, formulation development and commercial-scale oral dosage manufacturing.

For pharmaceutical procurement teams, emerging programs such as Khartis create an opportunity to monitor suppliers before demand becomes commercial-scale.

Important supplier-selection criteria could include:

1. API development capability — experience handling complex small-molecule candidates.

2. Analytical infrastructure — impurity profiling, stability testing and release testing.

3. Scale-up capability — ability to move from clinical quantities to commercial production.

4. Regulatory readiness — GMP systems and documentation appropriate for clinical and commercial supply.

5. Supply continuity — multiple manufacturing options for critical intermediates and APIs.

6. Cost competitiveness — particularly important if an oral therapy eventually competes with high-cost biologics.

7. Geographic diversification — reducing dependence on a single manufacturing region.

This could eventually make TED-related pharmaceutical supply chains more diversified as multiple therapeutic formats enter the market.

What Investors Will Watch Next

Khartis' financing provides resources to move its lead program toward the clinic, but the company's competitive position will ultimately depend on clinical evidence.

The most important upcoming milestones will include:

• first-in-human clinical development;

• safety and tolerability data;

• pharmacokinetic performance;

• evidence of target engagement;

• changes in proptosis and diplopia;

• durability of response;

• comparison of dosing convenience with injectable therapies;

• regulatory progress;

• potential expansion into additional immunology indications.

The central question will be whether oral selective IGF-1R inhibition can provide sufficient efficacy and safety to justify replacing or complementing established biologic therapies.

Outlook

The thyroid eye disease market is moving from a single-product success story toward a multi-player competitive landscape.

Amgen's Tepezza established IGF-1R inhibition, Viridian's Lumvoa has introduced a second approved option, and Khartis is now pursuing an oral approach that could potentially address one of the biggest practical limitations of infusion-based treatment.

Khartis is still early in development, so it is premature to conclude that its candidate will outperform existing therapies. Nevertheless, its emergence signals an important shift in drug development: once a target is clinically validated, innovation can increasingly focus on making established mechanisms more convenient, selective and commercially scalable.

For the broader pharmaceutical market, TED could therefore become an example of how a validated biological target evolves from first-in-class therapy into a competitive ecosystem of differentiated treatment formats.